A randomized, double-blind crossover study to investigate the analgesic efficacy of the bradykinin (B2) antagonist icatibant for propofol injection pain in healthy adult participants.

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521354-42-00

Acronym

PIP-Icat

Enrollment

Registered

2025-08-14

Start date

Unknown

Completion date

Unknown

Last updated

2025-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Brief summary

Area under the curve of Visual Analog Scale pain ≥ 30 mm (0-100 mm) - AUCVAS≥30

Detailed description

Max electronic Visual Analog Scale (VAS) pain (0-100 mm)

Interventions

DRUGPropolipid

DRUGNatriumklorid ”B. Braun”

DRUGinfusionsvæske

DRUGopløsning

DRUGICATIBANT

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Area under the curve of Visual Analog Scale pain ≥ 30 mm (0-100 mm) - AUCVAS≥30	—

Secondary

Measure	Time frame
Max electronic Visual Analog Scale (VAS) pain (0-100 mm)	—

Countries

Norway

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026